Company Overview of N30 Pharmaceuticals, Inc.
N30 Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops medicines that promote human organ repair, regeneration, and healing. The company provides N6022, a modulator of s-nitrosoglutathione reductase that completed Phase 2a testing. It offers S-Nitrosoglutathione reductase inhibitor drugs that are useful for pulmonary, gastrointestinal, cardiovascular physiology, and pathophysiology. N30 Pharmaceuticals, Inc. was founded in 2007 and is based in Boulder, Colorado.
3122 Sterling Circle
Boulder, CO 80301
Founded in 2007
Key Executives for N30 Pharmaceuticals, Inc.
Chief Financial Officer and Vice President of Finance & Administration
Executive Vice President of Product Development & Regulatory
Vice President of Research
Compensation as of Fiscal Year 2014.
N30 Pharmaceuticals, Inc. Key Developments
N30 Pharmaceuticals, Inc. Appoints Jon Congleton as Director, President and CEO
Dec 22 14
N30 Pharmaceuticals, Inc. announced that the company's board of directors has appointed Jon Congleton to the position of President and Chief Executive Officer. Congleton will also join the company's board of directors. Congleton brings more than twenty-five years of senior management and product commercialization experience in the pharmaceutical industry to N30 Pharma. Congleton was previously at Teva Pharmaceuticals Ltd., where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Central Nervous System Global Franchise, Senior Vice President of the Global Medicines Group, and General Manager of Teva Neuroscience, Inc.
N30 Pharmaceuticals, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014
Jun 10 14
N30 Pharmaceuticals, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 . Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States.
N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy
Mar 12 14
N30 Pharmaceuticals, Inc. announced that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). In preclinical studies, N91115 has been shown to rescue or "correct" F508del-CFTR, the most commonly occurring mutation in CF. It is the first oral GSNOR inhibitor to enter clinical development, and represents an important step forward in the development of more effective treatments for this serious disease. The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered N91115 will evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 40 healthy adults. N30 Pharma is also conducting a multicenter, dose escalation, safety study of N6022, its intravenous GSNOR inhibitor, in patients who are homozygous for F508del-CFTR. That study is currently enrolling the final cohort, at the high dose, with completion expected in the second quarter of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 18, 2014